X-BIOTIX THERAPEUTICS ANNOUNCES CHANGE IN CORPORATE STRATEGY

  29 April 2021

X-Biotix Therapeutics, Inc. (X-Biotix), a biotechnology company focused on the discovery and development of first-in-class antibiotic compounds targeting multi-drug-resistant Gram-negative pathogens, announced today a change in its strategy, which will include suspension of its current antibacterial research efforts. The company will instead focus on submitting manuscripts that describe its progress in developing novel small molecules that demonstrate inhibitory activity against multi-drug resistant Gram-negative bacteria and on strengthening its intellectual property position with additional filings. X-Biotix has developed comprehensive intellectual property covering a wide range of novel chemical matter for its research programs and will continue to explore out-licensing or new funding opportunities for these programs. The company hopes that, in light of the urgent threat of antimicrobial resistance that exists globally, appropriate funding and sponsorship will emerge to facilitate continuation of its critical early-stage work in this field.  

Further reading: X-Biotix
Author(s): Stephen T. Isaacs
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

Evotec

JSS University

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS





Global Ambassador Network

Welcome at the AMR Insights Ambassador Network!

The AMR Insights Ambassador Network is a growing, distinctive group of professionals who stand out for their commitment, willingness to cooperate and open attitude to combat Antimicrobial resistance (AMR).

More information and free-of-charge registration
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!